Axovant Gene Therapies Ltd.

Axovant Gene Therapies is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurodegenerative diseases. Their current pipeline of gene therapy candidates target GM1 gangliosidosis, GM2 gangliosidosis (also known as Tay-Sachs disease and Sandhoff disease), and Parkinson’s disease. Axovant is focused on accelerating product…More candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations.